Sanofi and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd., will co-develop and co-commercialize asset TEV’574, currently in Phase 2b trials for the treatment of Ulcerative Colitis and Crohn’s Disease, two types of inflammatory bowel disease. Under the new collaboration agreement, Teva will receive an upfront payment of $500 million and up to $1 billion in development and launch milestones. Each company will equally share the development costs globally and...